Correlation between Serum and Tissue Markers in Breast Cancer Iraqi Patients

Abeer M. Hussain1*, Alia Hussein Ali1 Haider Latif Mohammed2

1Department of Biology, College of Science for Women, University of Baghdad, Baghdad, Iraq. 
2Consultant in pathology (FICMS, Path., MBCHB)/ Ministry of Health, AL-Wasity teaching hospital.

*Corresponding author: abeer.m@csw.uobaghdad.edu.iq, aliaha_bio@csw.uobaghdad.edu.iq, haiderlateef5@gmail.com

ORCID ID: http://orcid.org/0000-0002-8452-6127*, http://orcid.org/0000-0001-5573-5942.

Received 12/12/2019, Accepted 25/3/2021, Published Online First 20/11/2021, Published 1/6/2022

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract:
Breast cancer is the most prevalent malignancy among women worldwide, in Iraq it ranks the first among the population and the leading cause of cancer related female mortality. This study is designed to investigate the correlations between serum and tissue markers in order to clarify their role in progression or regression breast cancer. Tumor Markers are groups of substances, mainly proteins, produced from cancer cell or from other cells in the body in response to tumor. The study was carried out from April 2018 to April 2019 with total number of 60 breast cancer women. The blood samples were collected from breast cancer women in postoperative and pretherapeutic who attended teaching oncology hospital of the medical city in Baghdad and the serum markers evaluated by ELISA technique are Carbohydrate Antigen 15-3 (CA 15-3), Carbohydrate Antigen 27.29 (Ca 27.29), Anti-Mullerian Hormone (AMH), Tumor Necrosis Factor-Alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-10 (IL-10) and Human Epididymis Protein-4 (HE4). Tissue samples were collected for the same breast cancer women who attended medical city, Baghdad with total number 30. The tissue markers evaluated by Immunohistochemical technique are Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (Her 2/neu) and Cyclin E. The results showed a positive significant correlation (p = 0.017) between Ca 27.29 and Her-2/neu, (p = 0.038) between IL-6 and cyclin E phenotype, (p = 0.051) between TNF-α and Cyclin E intensity, (p = 0.005) between HE4 and Her-2/neu, and negative significant correlation (p = 0.058) between IL-10 and ER score and (p = 0.045) between HE4 with Cyclin E intensity. We conclude from these correlations that positive correlations increasing disease progression, like correlation between Ca 27.29 and Her-2/neu, cyclin E with IL-6 and cyclin E with TNF-α. And the negative correlations may contribute to delay disease, like correlation between IL-10 and ER. From the correlations results in this study, it is clear that the Ca 27.29, Her-2 / neu, cyclin E markers play an important role in disease progression.

Keywords: Anti-Mullerian hormone (AMH), Breast cancer, Ca 15-3, Estrogen Receptor(ER), Human Epididymis Protein-4(HE4), Tumor Necrosis Factor-Alpha (TNF-α).

Introduction:
Breast cancer is one of the most common cancers in women. It is the most diagnosed cancer that causes death in women with a higher incidence in developing countries and higher death rates in developing countries 1,2. In Iraq, breast cancer ranks the first among the women and the leading cause of cancer related female mortality. Numerous studies from Iraq indicated that up to the present time a considerable rate of female patients still present with breast cancer at younger age groups with more advanced stages and aggressive tumor compared to their western counterparts. Ultimately leading to undesirable prognosis 3. In Iraq, about 34.27% of new cases register for breast cancer in female in Iraqi women until 2016 4.

Carbohydrate antigen Ca15 – 3, is a glycoprotein antigen. It is found on surface of cancer cell and sheds into blood stream and can be measured in saliva that is considered as blood stream in oral cavity that can be used for the detection of cancer begin and follow – up 5. CA 15-3 is useful for determining prognosis of breast cancer and also for monitoring the efficacy of the treatment since the elevated level of this tumor
marker in serum tend to increase the severity of breast cancer 4.

Tumor marker Ca 27.29 is a carbohydrate–containing protein antigen that reported as a tumor marker for breast cancer and it is called "Breast Carcinoma-associated antigen" 7. The Ca 27.29 considered as the tumor marker which breast cancer cell shed copies from Ca 27.29 protein to blood stream 8.

Anti – Mullerian hormone (AMH, also called a Mullerian inhibiting substances (MIS) or Mullerian inhibiting factor) was described at first in 1947 by Alfred Jost. It is produced by Sertoli cell in testis and it has a role during embryogenesis by inhibiting the development of Mullerian duct in male embryo so, it plays a role in male sex differentiation 10. The AMH activity is exerted by two receptors: Type I receptor and Type II receptor present on the AMH target organs such as gonads and Mullerian ducts 11. The AMH type II receptor expressed in normal and tumor tissue in breast and limited laboratory finding suggest a protective role of AMH in breast carcinogenesis 12. In other study showed the lowered concentrations of AMH in breast cancer patients and chemotherapy have a high effect on AMH level 13.

Tumor Necrosis factor alpha (TNF – α) is an inflammatory cytokine synthesized and secreted by many cell types especially macrophage, natural killer cell (NK) and T – cell. This cytokine has a central role in promoting inflammation, endothelial activation and has a significant role in cancer pathogenesis 14. The TNF – α is expressed by normal breast epithelial cells, but high level expressed in tumor cells from most breast cancer patients and the high level of TNF – α correlated with recurrence and advanced disease 15. The TNF – α is a necrotic factor in tumor microenvironment that stimulates tumor growth and migration and the elevated level related with metastasis 16. On the other hand, reports of the anti-proliferative and apoptotic effect of TNF-α on breast cancer have only been executed on the MCF-7 cell line 17. Some studies have shown that TNF-α may have a double-edged role in angiogenesis, depending on the used doses. High doses of TNF-α inhibit angiogenesis in mice while low doses promote vascularization of the area. The anti-angiogenic effect of TNF-α is related with the down-regulation of adhesion molecules, while pro-angiogenic responses have been associated with the increased expression of VEGF, VEGFR, IL-8, and FGF. Therefore, low levels of TNF-α increase tumor growth, induce angiogenesis of several tumors in mice, and stimulate tumor-associated myeloid cells and the co-expression of endothelial and myeloid markers with pro-angiogenic/pro-vascular properties 18.

Interleukin – 6 (IL – 6) is a pro-inflammatory cytokine, it is produced by macrophage and monocyte. IL – 6 is expressed by multiple tumor tissue like breast, prostate, colorectal and ovarian cancer 19. An elevated serum level of IL – 6 is shown to be correlated with disease staging and undesirable outcomes in women with metastatic breast cancer and it has a role in tumor advancements 20. The IL – 6 has a central role in tumor behavior like tumor growth, cell proliferation, migration and invasion, angiogenesis and metastasis 19.

Anti – inflammatory cytokine, (IL – 10) gene are located on chromosome 1 at q31-32. It is produced by immune cell like T – lymphocyte, macrophage and natural killer cell (NK) 22. It has an important role in breast carcinogenesis. IL-10 might promote tumor development; by suppress anti-tumor immune responses 22.

Human Epididymis protein – 4 (HE 4) discovered by Kirchoff et al, in 1991 was first identified in males in distal epithelium of Epididymis 23. It has 124-amino acid long polypeptide 24. The HE 4 gene is localized on human chromosome 20q12 – 13 23. The HE 4 is reported expressed in many normal and malignant tissues, breast epithelium, female genital tract, Epididymis, vas deference, distal renal tubules, respiratory epithelium, colon mucosa and salivary glands all show HE 4 immuno-reactivity 25. The HE 4 is expressed in ductal carcinoma of breast cancer tissue 26.

Estrogen and progesterone receptors are hormone receptors found on breast cells that pick up hormone signals resulting in cell growth 27. In breast cancer status the determination of these receptors is useful for therapeutic options and provide prognostic information 28. Human epidermal growth factor receptor (Her – 2) was first discovered in 1984 by Weinberg and associated 29. The gene that encoded to this receptor is situated on chromosome 17q 30. It is called as a neu in rat, the gene expression result production 185kDa transmembrane glycoprotein known as her – 2 proteins and have extracellular domain (ECD) 31.

Cyclin E / CCNE1 gene is localized on chromosome 19q 32. Cyclin E is nuclear protein identified through it is capacity of division abnormality in cyclin – deficient yeast cells. Cyclin E has a high expression in many human cancers including breast, endometrium, lung, cervix, gastrointestinal tract and lymphoma. The high cyclin E expression was prognostic factor which correlated with worse patient outcome in women with breast cancer 33.
This research discusses a group of serum and tissue markers in a group of Iraqi women with breast cancer. The research clarifies the correlations between these markers because of their importance in the progression of the disease or its regression.

Materials and Methods:

Sixty patients (32-75 years old) who admitted the Oncology Teaching hospital, Medical City-Baghdad confirmed as breast cancer by physical examination, biopsy tacking, ultrasound and mammogram. Postoperatively patients followed – up for defining the histopathology classification of breast cancer stage and lymph node metastasis were recorded. The patients did not receive chemotherapy, radiotherapy or hormonal therapy yet.

Blood samples

The blood was collected from patients by 5 ml disposable syringe and then was put in gel clot activator tube and left room temperature to allow clotting after that entered to centrifugation 3000 rpm for 15 minutes then serum distributed in 4 eppendorf tubes in equal amount and stored in deep freeze until time to use.

Kits used

The all serum biomarkers (Ca 15-3, Ca 27.29, AMH, IL-6, IL-10, TNF-α and HE4) for breast cancer women were evaluated depending on sandwich ELISA principles using three antibodies, capture antibody, detection antibody and HRP-linked secondary antibody. The sample with unknown amount of antigens is immobilized on wells of the plate by bind with capture antibody. The antigen-antibody complex is linked to an enzyme-bound secondary antibody. In the final step a substrate is added that the enzyme can convert to some detectable signal like color \(^{34}\). The Ca15-3 kit purchased from Thermofisher (USA), Ca27.29 kit from Mybiosource (USA). The AMH kit is from Kamiya biomedical (USA). The TNF-α, IL-6 and IL-10 kits are from Thermofisher (Austria). The HE4 kit is from Casabio (China). Tissue markers were evaluated by Immunohistochemical technique. The ER, PR and Her-2/neu kits from Zytomed system (Germany) and cyclin E kit from Bio SB (USA). The method of action of the serum markers was according to was mentioned in the kit used for each marker.

Clinico-pathological Features

The clinic-pathological features of patients female are illustrated in Tables 1 and 2.

| Table 1. Illustrated the patient ages and body mass index (BMI) means for patients studied.
| Two sample t test showed differences between means of age and body mass index according to studied groups. |
| Groups | N | Mean ± S.D | P value |
|---|---|---|---|
| Age | Breast cancer women | 60 | 52.20 ± 9.940 | 0.532 |
| Body mass index | Breast cancer women | 60 | 31.22 ± 5.852 | 0.188 |
| Control | 20 | 29.30 ± 4.703 |

Table 2. Illustrated the patients children number, smoking, chronic disease, breast feeding, family History, type of tumor, stage and grade.

| No | Studied Variables | Total Number (60) |
|---|---|---|
| 1 | Children Number | 52 |
| 2 | Yes (have children) | 52 |
| 3 | No (have no children) | 8 |
| 4 | Smoking | 3 |
| 5 | Yes(smoker) | 3 |
| 6 | No( Non smoker) | 57 |
| 7 | Hypertension | 22 |
| 8 | Yes (have hypertension) | 22 |
| 9 | No( have not hypertension) | 38 |
| 10 | Diabetes | 8 |
| 11 | Yes (have diabetes) | 8 |
| 12 | No(not have diabetes) | 52 |
| 13 | Breast Feeding | 51 |
| 14 | Yes (breast feed) | 51 |
| 15 | No (no breast feed) | 9 |
| 16 | Oral Contraceptive pills | 3 |
| 17 | Yes(taking contraceptive pills) | 3 |
| 18 | No( not taking contraceptive pills) | 57 |
| 19 | Family History | 3 |
| 20 | Yes(have first-degree history) | 3 |
| 21 | No( have no-first-degree history) | 57 |
| 22 | Type of Tumor | 3 |
| 23 | Ductal Carcinoma In Situ (DCIS) | 4 |
| 24 | Invasive Ductal Carcinoma (IDC) | 52 |
| 25 | Invasive Lobular Carcinoma (ILC) | 4 |
| 26 | Stage | 6 |
| 27 | Stage I | 6 |
| 28 | Stage II | 28 |
| 29 | Stage III | 26 |
| 30 | Grade | 2 |
| 31 | Grade I | 2 |
| 32 | Grade II | 43 |
| 33 | Grade III | 15 |

Tissue samples

The immunohistochemistry is a technique for identifying cellular or tissue antigens by mean antigen-antibody interactions. The IHC staining is complete by using enzyme-labeled (immunoperoxidase) antibodies to identify proteins.
The secondary antibody is reactive against the primary antibody conjugated or linked to an enzyme marker. Finally, the color of the reaction is determined by precipitating chromogen, usually Di Amino Benzidine (DAB) (brown color) with which the enzyme react 35. Tissue samples (Formalin Fixed Paraffin Embedded Tissue "FFPE") were collected from 30 patients who admitted to tissue laboratory, Oncology Teaching hospital, Medical City-Baghdad. The desired information about the patients and histopathological information of the tumors were collected from the patients’ files. The tissue section slides of ER, PR, Her – 2 / neu and Cyclin E receptors were imaged by using light Microscope (leica) and camera (leica) by 10 x and 40 x objective lenses and magnification power at 100 X and 400 X.

Tissue Preparation for immunohistochemistry

Reagents Preparation

1 - Reagents should be at room temperature when used.
2 - Deparaffinise and rehydrate paraffin-embedded tissue sections.
3 - Pre-treatment with HIER (Heat Induced Epitope Retrieval).
4 - The tissue sections have to be completely covered with the different reagents in order to avoid drying out.
5 - Preparation of the chromogenic substrate DAB working solution. Add 4 drops (200 μl) of DAB concentrate to one bottle of DAB substrate buffer and mix thoroughly.

Staining Procedure

The procedure of the ER, PR and Her2/neu by IHC assay in this study is carried out in accordance with the manufacturer instructions (Zytomed system, Germany).
1- Peroxide block (3% H2O2 solution).
2- Washing with wash buffer.
3- Primary antibody used.
4- Washing with wash buffer.
5- Biotinylated secondary antibody.
6- Washing with wash buffer.
7- Streptavidin-HRP-conjugate.
8- Washing with wash buffer.
9- DAB adding.
10- Stopping the reaction with distilled water when the desired color intensity is attained.
11- Counterstaining and bluing.
12- Mounting: permanent with DAB.

The ER and PR section was read according Allred score (proportional percentage + intensity of staining) of tumor cells and according the intensity of staining cells for Her-2/neu and these reading according to Iqbal BM and Buch A, 2016 36 (Tables 3 and 4).

### Table 3. The Allred score (proportional + intensity) for ER and PR 36.

| N  | Allred score | Final result |
|----|--------------|--------------|
| 1  | 0/8          | Negative     |
| 2  | 1/8 – 2/8    | Negative     |
| 3  | 3/8 – 4/8    | + Ve Weak    |
| 4  | 5/8 – 6/8    | + Ve Moderate|
| 5  | 7/8 – 8/8    | + Ve Strong  |

### Table 4. The score of Her-2/neu depend on intensity of staining cells 36.

| N  | Staining Pattern | Score of Her-2 |
|----|------------------|----------------|
| 1  | No staining the tumor cells < 10 % | 0 -Ve |
| 2  | Faint / incomplete membrane staining in tumor cells > 10 % | +1 (-Ve ) |
| 3  | Weak to moderate complete membrane staining in tumor cells > 10 % | +2 (+Ve ) |
| 4  | Strong complete membrane staining in tumor cells > 10 % | +3 (+Ve ) |

Immunohistochemical reading for cyclin E protein is divided into two types according to Karakas C et al, 2016 37 (Tables 5 and 6).

### Table 5. The first reading of cyclin E according to phenotype 37.

| N  | First reading according to Phenotype |
|----|-------------------------------------|
| 1  | Phenotype I = no nuclear and No cytoplasm |
| 2  | Phenotype II = + nuclear and No or weak cytoplasm |
| 3  | Phenotype III = + nuclear and + cytoplasm |
| 4  | Phenotype IV = no or weak nuclear and + cytoplasm |

### Table 6. The second reading of cyclin E according to intensity of tumor cells 37.

| N  | Second reading according to Intensity of tumor cells |
|----|-----------------------------------------------------|
| 1  | No Stain |
| 2  | Weak |
| 3  | Intermediate |
| 4  | Strong |

### Statistical analysis

The statistical analysis was performed using the statistical package SPSS version 23. Results were considered at significant (P<0.05) difference levels. The correlation test was used to find out significance of correlation between related variables.

### Results:

The mean of serum markers of patients samples are clarified in Table 7 and Fig. 1.
Table 7. The differences between serum markers according to studied groups.

| Variables | Groups | N  | Mean ± S.D    | P value |
|-----------|--------|----|--------------|---------|
| Ca 15-3 (U/ml) | Cases | 60 | 35.450 ± 4.7136 | 0.001   |
|           | Control | 20 | 8.180 ± 2.3210 |         |
| Ca 27.29 (U/ml) | Cases | 60 | 113.300 ± 17.3120 | 0.001   |
|           | Control | 20 | 12.485 ± 4.8788 |         |
| AMH (ng/ml) | Cases | 60 | 0.6172 ± 0.17960 | 0.001   |
|           | Control | 20 | 2.0450 ± 0.44895 |         |
| IL-6 (pg/ml) | Cases | 60 | 113.300 ± 17.3120 | 0.001   |
|           | Control | 20 | 12.485 ± 4.8788 |         |
| IL-10 (pg/ml) | Cases | 60 | 8.793 ± 2.3440 | 0.001   |
|           | Control | 20 | 2.830 ± 0.7371 |         |
| TNF-α (pg/ml) | Cases | 60 | 25.963 ± 6.9211 | 0.001   |
|           | Control | 20 | 4.658 ± 1.5869 |         |
| HE4 (pmol/L) | Cases | 60 | 91.247 ± 29.4110 | 0.001   |
|           | Control | 20 | 15.755 ± 5.5766 |         |

Ca 15-3 = Carbohydrate Antigen, Ca27.29 = Carbohydrate Antigen, AMH = Anti-Mullerian Hormone, (TNF-α) = Tumor Necrosis Factor Alpha, (IL-6) = Interleukin 6, (IL-10) = Interleukin 10, HE4 = Human Epididymis Protein 4.

Figure 1. The graphs showing the means of serum markers for control and female patients.

This research showed that 70 % from cases were ER and PR positive as shown in Table 8. The Her-2/neu results showed 33% from cases were negative as shown in Table 9. While cyclin E phenotype showed 46% from cases were phenotype III and 33% from cases were strong staining cells as shown in Tables 10,11.

Table 8. The percentage of ER and PR tissue samples.

| ER and PR Phenotype | Number | Percentage % |
|---------------------|--------|--------------|
| ER + / PR +         | 21     | 70           |
| ER + / PR -         | 0      | 0            |
| ER - / PR +         | 1      | 3.3          |
| ER - / PR -         | 8      | 26.6         |
| Total               | 30     | 100          |

Table 9. The percentage of Her-2/neu tissue samples.

| Her – 2 / neu status | Number | Percentage % |
|----------------------|--------|--------------|
| Score 0 Negative     | 10     | 33.3         |
| Score 1 Negative     | 6      | 20           |
| Score 2 Positive     | 7      | 23.3         |
| Score 3 Positive     | 7      | 23.3         |
| Total                | 30     | 100          |

Table 10. The percentage of phenotype cyclin E tissue samples.

| Cyclin E / phenotype | Number | Percentage % |
|----------------------|--------|--------------|
| Phenotype I           | 3      | 10           |
| Phenotype II          | 11     | 36.6         |
| Phenotype III         | 14     | 46.6         |
| Phenotype IV          | 2      | 6.6          |
| Total                | 30     | 100          |
The results revealed correlations between the means of serum markers and tissue markers in breast cancer patients. The results showed that there was a positive significant correlation between Ca 27.29 with Her-2 P (0.017), HE 4 with Her-2 P (0.005), IL – 6 and cyclin E phenotype P (0.038), TNF – α with cyclin E intensity P (0.051) and revealed a negative significant correlation between IL – 10 and ER score P (0.058) and HE 4 with cyclin E intensity P (0.045) as in Table 12.

### Table 11. The percentage of intensity of cyclin E tissue samples.

| Cyclin E intensity | Number | Percentage % |
|--------------------|--------|--------------|
| No stain           | 3      | 10           |
| Weak               | 8      | 26.6         |
| Intermediate       | 9      | 30           |
| Strong             | 10     | 33.3         |
| Total              | 30     | 100          |

### Table 12. The correlation between serum and tissue markers in studied breast cancer patients.

|       | ER score | PR score | Her-2/neu | Cyclin E Ph. | Cyclin E int. |
|-------|----------|----------|-----------|--------------|---------------|
| Ca 15.3 (U/ml) Sig. | -0.080   | -0.291   | 0.116     | 0.173        | 0.133         |
| Ca 27.29 (U/ml) Sig. | 0.082    | -0.011   | 0.432*    | 0.072        | -0.061        |
| AMH (ng/ml) Sig.     | -0.537   | 0.339    | 0.214     | 0.975        | 0.911         |
| IL-6 (pg/ml) Sig.    | -0.331   | -0.020   | 0.381*    | 0.060        |               |
| IL-10 (pg/ml) Sig.   | 0.155    | 0.074    | 0.918     | 0.038        | 0.752         |
| TNF - α (pg/ml) Sig. | 0.058    | 0.069    | 0.406     | 0.667        | 0.314         |
| HE 4 (pmol/L) Sig.   | 0.032    | 0.153    | 0.495**   | -0.223       | -0.368*       |

*CC = Correlation Coefficient

Ca 15-3 = carbohydrate antigen, Ca27.29 carbohydrate antigen, AMH = Anti-Mullerian hormone, IL-6 = interleukin 6, IL -10 = interleukin 10, TNF-α = tumor necrosis factor alpha, HE 4 = human Epididymis protein 4, ER = estrogen receptor.

### Tissue sections

In invasive breast carcinoma the negative status of estrogen receptor (ER) and progesterone receptor (PR) mean that no ER and PR expression (0%) staining cells and the nuclear staining < 1% of total cancer cells as illustrated in Fig. 2, while the levels of (ER) and (PR) expression were positively 70% (90-100%) from cancer cells reaction with immunostaining and strong intensity as showed in Figs 3 and 4.

Her-2/neu is a cell membrane receptor and its staining depends on the intensity of cancer cells staining. Figure 5a shows no cancer cells staining because these cancer cells did not express of her-2/neu receptor, while in Figs 5b and c respectively shows reaction between her-2/neu receptor with immunostaining.

The Fig. 6a shows the phenotype II of cyclin E expression that occur nuclear staining exceeded cytoplasmic staining and Fig. 6b the phenotype III of cyclin E that was nuclear and cytoplasmic staining are equal. Figure 6c shows the moderate staining of cancer cells because the moderate levels of cyclin E expression. Figure 6d reveals a strong staining due to the high levels of cyclin E expression in breast cancer cells.

![Figure 2. Poorly differentiated invasive breast ductal carcinoma showing negatively immunohistochemical of Estrogen receptor staining with background of counter stain.400 X.](image)
Figure 3. Moderately differentiated invasive breast ductal carcinoma. The arrow shows 95% proportional positive immunohistochemical nuclear staining for Estrogen receptor antibody with strong intensity. 400 X.

Figure 4. Poorly differentiated invasive breast ductal carcinoma. The arrow shows immunohistochemical nuclear staining for Progesterone receptor antibody about 90% proportional with moderate intensity. 400 X.

Figure 5. (A) Poorly differentiated invasive breast ductal carcinoma showing weak interrupted membranous staining for Her 2/neu antibody using IHC technique, more than 10% of malignant cells score (-1) negative. 100 X. (B) Moderately differentiated invasive breast ductal carcinoma, the arrow shows moderately membranous staining for Her2/neu antibody by IHC technique for more than 10% of malignant cells. Score (+2) equivocal (weak positive). 400 X. (C) Moderately differentiated invasive breast ductal carcinoma, the arrow shows a complete membranous staining for Her2/neu antibody using IHC technique for more than 10% of malignant cells. Score (+3) (Strong positive). 400 X.
Figure 6. (A) Invasive breast ductal carcinoma, the arrow shows cyclin E phenotype II positive nuclear and weak cytoplasm. 400 X. (B) Invasive breast ductal carcinoma showing cyclin E antibody phenotype III positive nuclear and positive cytoplasm by using IHC technique. 400 X. (C) Moderately differentiated invasive breast ductal carcinoma showing cyclin E antibody by IHC technique. The arrow shows moderate (M) intensity. 400 X. (D) Moderately differentiated invasive breast ductal carcinoma showing cyclin E antibody using IHC technique. The arrow shows strong (S) intensity. 400 X.

Discussion:

This research explained that the correlations between serum and tissue markers have an important role in the progression or regression of breast cancer through the effect of each marker on the other marker. The negative correlation (p < 0.05) between ER and IL-10 in our research Corresponds with Zhuangwei et al., who reported a high serum IL-10 correlated with ER negative expression 38. Bhattacharjee et al., also revealed a significant correlation between IL-10 with ER and PR -ve tumors and IL-10 expression correlated with ER,PR -ve and Her-2/neu +ve significantly (p = 0.01) and this subtype of breast cancer (ER,PR -ve and Her-2 +ve) considered as the worst prognosis among the other subtypes 39. Sheikhpour et al., reported that IL-10 over-expressed in ER –ve and interpreted that expression of activator protein (AP – 1) is high in ER –ve in compared with ER +ve due to increased AP-1 expression in related with IL-10 41.

The AP-1 is transcription factor regulates gene transcription and it is implicated in regulating many physiological and pathological cellular process like proliferation, differentiation, growth, programmed cell death, cell migration and transformation. AP-1 mediated gene expression in response to inflammatory cytokine and it important for the pathogenesis of disease 40. Carruba et al., concluded that estrogen hormone (E2) is essential regulators of cytokine in culture macrophage, the results reported that E2 induced decrease IL-10 secretion and that estrogen play a role in reduce IL-10 production 41.

The positive correlation (p < 0.05) between Ca 27.29 and Her-2/neu markers in our study agrees with Yerushalmi et al., who explained a significant correlation between Ca 15-3 and Her-2/neu 42. We
suggest the correlation between Ca 27.29 and Her-2/neu is similar to the correlation between Ca 15-3 and Her-2/neu and that's because both of Ca 15-3 and Ca 27.29 are products for the same MUC1 gene 43. The experiments about breast cancer revealed that MUC1 RNA expression was the highest in Her-2/neu over-expression in tumor patients samples, the results reported that when treating cells with concentrated lapaatinib (specific tyrosine kinase inhibitor of Her-2/neu) it causes a decrease in MUC1 expression and in another experiment on MDA-MB-361 cell line when treated cell with lapaatinib showed that decrease Her-2/neu phosphorylation and a significant reduction in MUC1 levels 44. The Her-2 receptor is over-expressed in human breast cancer cells and the MUC1 associated with Her-2 at the surface of breast cancer cells, MUC1 formed from N-terminal (MUC1-N) and C-terminal (MUC1-C) fragments The MUC1-C associated with Her-2 receptor. The results revealed that MUC1-C cytoplasmic domain is sufficient to form complexes with Her-2 and this connection contributed to Her-2 activation and in carcinoma cells that suffered from epithelial-mesenchymal transition. The MUC1-C interact with Her-2 complex and promote activation of Her-2 by this way the breast cancer cells appear have sabotaged the physiological response to support their growth and survival 45.

The results of study revealed a positive correlation (p < 0.05) between HE 4 and Her-2 in breast cancer. This result agree with result of Akoz et al. on breast cancer between Her-2 expression and HE 4 staining intensity by immunohistochemical technique and demonstrated that in breast tumors, the increasing of Her-2/neu amplification was in parallel with HE 4 staining intensity, Her-2/neu amplification is known as poor prognostic factor for breast cancer and proved that HE 4 expression also unfavorable prognostic factor in breast cancer 46. The HE 4 protein enhance the proliferation, invasion and metastatic ovarian cancer cells and have the same biological effects on endometrial cancer, HE 4 can improve cell viability and found that HE 4 may play an essential role in EGFR (epidermal growth factor receptor) activation 47. The EGFR also known (Her-2), EGFR (Her-2) is over-expressed in breast carcinoma and this over-expression due to EGFR (Her-2) gene amplification that can observed in many cancer types like breast, lung, colorectal and esophageal cancers 48. So the increase of HE 4 in patients can induce to increase effectiveness EGFR (Her-2) that also increased in breast tumor.

The positive correlation (p < 0.05) between IL-6 and cyclin E agree with Wei et al, who demonstrated that IL-6 able to suppress cyclin – dependent kinase 2 (CDK 2) activity by accumulation P27kip1 protein 49. Pan, Y. and Claret, F. X. concluded that IL-6 interact with Jab1/Csn5 to regulate un-phosphorylated STAT3 and the decrease of Jab1/Csn5 expression cause decrease un-phosphorylated STAT3 and that STAT3 bind to Jab1/Csn5 to increased it promoter activity with increase Jab1/Csn5 transcription in breast cancer while, decrease STAT3 caused lowering Jab1/Csn5 promoter activity and Jab1/Csn5 protein expression. The IL-6 was important activators of STAT3 and contributed IL-6 to activation Jab1/Csn5 transcription and expression by STAT3 50. The Jab1/Csn5 gene is located on chromosome 8 and the expression of Jab1/Csn5 was found aberrantly expressed about 50 % in primary breast tumors and 90 % in metastatic lesions 51. The Jab1/Csn5 over-expression is negatively correlated with P27 expression and that P27 can inhibit CDK and suppress cell-cycle 50. Also found that breast tumors with high levels of P27 expression were rarely positive for Jab1/Csn5 expression and Jab1/Csn5 protein expressed levels were higher in oncogenically transformed breast cells and tumors than normal mammary epithelium. The function of Jab1/Csn5 is to re-localizing P27 from nucleus to cytoplasm that inducing degradation P27 in cytoplasm by ubiquitin / proteasome pathway and finally, allowing breast tumor cells to progress into S phase 51.

The results revealed a positive correlation (p < 0.05) between cyclin E and TNF-α in breast cancer patients. This correlation was interpreted by indirect effects of cyclin E on TNF-α and as shown from results of Dhillon, N.K. and Mudryj, M. that revealed that cyclin E over-expression cause decreasing of BcL-2 protein levels in MCF-7 and T47D breast cancer cell lines 52. The MCF-7 is the first cancer cell line isolated from Catherine Frances in Michigan, and called (MCF-7) Michigan Cancer Foundation and after 7 attempts to generate a monolayer from cancer cells 53. The BcL-2 is over-expression in MCF-7 cell has suppress TNF-α and the response to TNF-α is increased in cyclin E over-expression cells and reported that an enhanced sensitivity of cyclin E over-expression cells to cytokine like TNF-α 52.

The negative correlation (p < 0.05) between HE 4 and cyclin E. Wang et al, interpreted the results on cell lines that HE 4 and ANXA 2 both localized in cell membrane and cytoplasm were over expressed and broadly interact in many malignant tumor cells, the cell lines that highly
expressed HE 4 and ANXA 2 considered have a greatest capability in migration, invasion, adhesion and proliferation and the interaction between HE 4 and ANXA 2 facilitate migration, adhesion, invasion and proliferation of malignant tumor cells. The ANXA 2 is Annexin 2 (ANXA 2) 36 – KDa calcium-dependent phospholipid binding protein in breast cancer, ANXA 2 participates in many cellular process including endocytosis, exocytosis of intracellular proteins, motility of cell, fibrino-lysis and ion channel constitution. The ANXA 2 is related to the occurrence and development of many malignant tumor and play a central role in angiogenesis, migration, apoptosis, adhesion, invasion and proliferation of tumor cells.

The ANXA 2 over-expressed in many solid tumors like lung, colorectal, pancreatic, breast and hepatocellular cancer. Wu et al, explained that ANXA 2 significantly increase expression both P21 and P27, but decreased expression of CDK1, CDK2 and cyclin B. The cyclin E / CDK2 are responsible for G1 to S phase transition in cell cycle. So, from these finding can conclude that HE 4 by interaction with ANXA 2 can inhibit or decrease levels of cyclin E.

The hormonal receptors results clarified a positive (ER+/PR+) were 70 % with negative (ER-/PR-) 26 %. Several studies have indicated that patients with positive hormonal receptors have a significantly higher survival rate, since positive status have benefits from hormonal treatment, where this not demonstrated in negative side. Several studies have shown survival advantages of ER/PR receptors in breast cancer, it has been found that this survival advantages is substantially enhanced by adjuvant hormonal therapy which was given to patient with ER/PR positive tumor by reducing the recurrence rate during treatment period and reducing breast cancer mortality, therefore ER/PR expression status are regarded a good prognostic factor and predictor factor for response to endocrine therapy. The patients with ER+/PR+ tumor had superior survival compared with patients with ER-/PR- tumor and the estimated risk of death was significantly higher in patients with ER-/PR- tumor compared with patients with ER+/PR+ tumor.

The results of Her-2/neu demonstrated that Her-2/neu negative were 53 % more than positive 46 %. It is well known that overexpression of Her2 gene is a significant predictor of both short overall survival and time to relapse in breast cancer patient, Trastuzumab (Herceptin), which is monoclonal antibodies against extracellular domain of Her-2/neu, became the standard adjuvant treatment in breast cancer patients who appeared overexpression of Her-2/neu. It has been proven that trastuzumab is an effective drug in improving survival for patients with early Her-2 positive breast cancer as well as metastatic Her-2 positive breast cancer.

In our study the cyclin E expression was 46 % phenotype III (+ nuclear and + cytoplasm) and 36 % phenotype II (+ nuclear and weak cytoplasm), patients with breast cancer whose tumors had no cytoplasmic cyclin E staining had an overall favorable prognosis, and those with any cytoplasmic cyclin E staining had a poor prognosis. We reported that LMW-E not full-length cyclin E, is most active in phosphorylating substrates and that LMW-E has a higher affinity than full-length cyclin E for binding CDK. LMW-E is more tumorigenic and patients whose tumors expressed LMW-E were shown to be at the highest risk for recurrence and death due to breast cancer. Because LMW-E lacks the nuclear localization of full-length cyclin E, the LMW-E accumulates in the cytoplasm, where it binds to CDK2 and retains kinase activity. The expression of cytoplasmic cyclin E is related to the aggressiveness of the disease. The function of nuclear cyclin E has been attributed to cell-cycle progression, and overexpression of nuclear cyclin E leads to deregulation of cell proliferation, while cytoplasmic cyclin E has alternate functions that can affect signal transduction and metabolism.

Conclusion:
The breast cancer is the common cancer that affected Iraqi women. The patients with higher serum of Ca 15-3, Ca 27.29 and elevated expression of ER, Her-2 and cyclin E levels are more likely to have breast cancer metastasis. So, both markers and by these correlations it has been demonstrated that they are as an indicator for helping clinicians to evaluate disease progression of breast cancer, predicting patient outcome and determining adjuvant treatment for better outcome.

Authors’ declaration:
- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are mine ours. Besides, the Figures and images, which are not mine ours, have been given the permission for re-publication attached with the manuscript.
- The author has signed an animal welfare statement.
- Authors sign on ethical consideration’s approval.
- Ethical Clearance: The project was approved by the local ethical committee in University of Baghdad.
Authors’ contributions statement:
A.M., A.H. and H.L. contributed to the research design, collect the samples, implementation of the research, to the analysis of the results and to the writing of the manuscript.

References:
1. AICR: American Institute of Cancer Research. Diet, Nutrition, Physical activity and breast cancer. World Cancer Research Fund. 2017. Pp: 4.
2. Martínez-Montiel N, Anaya-Ruiz M, Pérez-Santos M, Martínez-Contreras RD. Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes. 2017 Oct; 8 (217): 1 – 14. Available from www.mdpi.com/journalgenes DOI: 10.3390/genes8100217.
3. Alwan NAS, Shawkat MM. Treatment Options and Follow-Up among Iraqi Patients with Breast Carcinoma. European J of Med and Health Sci. 2020 March; 2 (2): 1 – 6. DOI: http://dx.doi.org/10.24018/ejmed.2020.2.2.171.
4. Annual Report, Iraqi Cancer Registry (ICR). 2016. Republic of Iraq, Ministry of Health/Environment Iraqi Cancer Board.
5. Velpula N, Yathavakilla ChN, Ramesh A. Tumor Markers- A Review. Int J of Oral Health Dentistry. 2017 Jan-Mar; 3 (1): 1 – 5. DOI: 10.18231/2395-499X.2017.0001.
6. Abed SN, Mahdi HS, Sahib AS, Abo Almaihi MMH, AL-Haydar M, Mohsin KK. Serum Levels of Cancer Antigen 15.3 and Estrogen in a Samples of Iraqi Women with Breast Cancer Treated with Anastrozole. Int J of Pharmaceut Res. 2020 Jan [2020 Jun]; 1: 1604–1608. DOI: https://doi.org/10.31838/ijpr/2020.SP1.246.
7. Kabel AM. Tumor markers of breast cancer: New prospective. J of Oncol Sci. 2017 Jan [2017 Jan 16]; 3 (1): 5 – 11. Available from http://dx.doi.org DOI: 10.1016/j.jons.2017.01.001.
8. Loeser A. The insiders guide to Metastatic Breast cancer. A Summary of the disease and its treatments. 2017. Pp: 7, 8.
9. Lehmann P, Vélez MP, Saument J, Lapensée L, Jamal W, Bissonnette F, et al. Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF. J Assist Reprod Genet, 2014 Feb [2014 Feb 27]; 31 (1): 493 – 498. DOI: 10.1007/s10815-014-0193-4.
10. Helena M. Anti-Müllerian hormone as a marker of ovarian reserve in girls before, during and after treatment for childhood cancer. MSc. Thesis. Lund University; 2017.
11. Saadullah SM, Sulaiman DM. Anti-Müllerian Hormone Level in Patients with Polycystic Ovary Syndrome. Med J of Babylon. 2018 Oct-Dec [2018]; 15(4): 295 – 299. Available from www.medjbabylon.org. DOI: 10.4103/MJBL.MJBL-98-18.
12. Eliassen AH, Zeleniuch-Jacquotte A, Rosner B, Hankinson SE. Plasma anti-Müllerian hormone concentrations and risk of breast cancer among premenopausal women in the Nurses’ Health Studies. Cancer Epidemiol Biomarkers Prev. 2016 May [2017 May 1]; 25 (5): 854 – 860. DOI: 10.1158/1055-9965.EPI-15-1240.
13. Kadhum NH. Determination Anti-Mullerian Hormone and Vitamin D in Breast Cancer patients. World J of Pharmaceut Res. 2017 Aug; 6 (9): 48–59. DOI: 10.20959/wjpr2017-9232.
14. Al-Dulaimy NH, Hassan AJ, Al-Araj SM. Estimation of Interferon-α (IFN-α) and Tumor Necrosis Factor-α (TNF-α) in Female Rats Immunized by Human Breast Cancer Cell Line T47D. J of Babylon University/Pure and Applied Sci. 2016; 9 (24): 2449 – 2455.
15. Katanov Ch, Lerrer Sh, Liubomirski Y, Leider-Trejo L, Meshel T, Bar J, et al. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-kB pathway. Stem Cell Res and Therapy. 2015 Apr [2015 May 1]; 6 (87): 1 – 17. DOI: 10.1186/s13287-015-0080-7.
16. Ma Y, Ren Y, Zhi-Jun D, Cai-Jun W, Yan-Hong J, Xu J. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 2017; 26 (3): 421 – 426. DOI: 10.17219/acem/62120.
17. Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor Necrosis Factor-α Blockade: An Opportunity to Tackle Breast Cancer. Front Oncol. 2020 Mar [2020 Apr 22]; 10: 1 – 25. Available from www.frontiersin.org DOI: 10.3389/fonc.2020.00584.
18. Zappavigna S, Cossu AM, Grimaldi A, Bocchetti M, Ferraro GA, Nicoletti GF, et al. Anti-Inflammatory Drugs as Anticancer Agents. Int J of Mol Sci. 2020 Apr [2020 Apr 9]; 21: 1 – 29. Available from www.mdpi.com/journal/ijms DOI: 10.3390/ijms21072605.
19. Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol, Immunotherapy. 2017 Dec [2017 Dec 18]; 67: 537 – 549. Available from http://doi.org DOI: 10.1007/s00262-017-2106-8.
20. Al.Thwani AN, Mohsin SM. Serum level of Interleukin-6 in Breast Cancer Iraqi Women. Iraqi J of Cancer and Med Genetics. 2012; 5 (1): 42 – 45.
21. Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak N, Nasiri R, Neamatzadeh H. A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative. Rep Biochem Mol Biol. 2018 Jul; 7 (1): 30 – 37.
22. Al-Ankoshy AAM, Alatbeeh AHD. The impact of IL-10 gene polymorphism on progressive Breast cancer. J Pharm Sci and Res. 2019; 11(1): 93-97.
23. Sirsikar M, Pinnelli VBV, Raghavendra DS. Diagnostic and Prognostic Performance of Human Epididymis Secretory Protein- 4 (HE4) in Cancer Treatment: A Review. World J of Pharmaceut Res. 2016 Dec; 5 (1): 406 – 420.
24. Celik B, Bulut T. Human epididymis protein 4 may not be a reliable screening biomarker for detecting
lung carcinoma patients. Biomed Rep. 2017 Aug; 7 (1): 297 – 300. DOI: 10.3892/br.2017.971.

25. Kemal Y, Demirag G, Bedir AB-K, Tomak L, Derebey M, Erdem D, et al. Serum human epidermidin protein 4 levels in colorectal cancer patients. Mol and Clin Oncol. 2017 Jul; 7 (1): 481 - 485. DOI: 10.3892/mco.2017.1332.

26. Gunduz UR, Guналı M, Isiksacan N, Gunduz S, Okutlar Y, Kocoglu H. A new marker for breast cancer diagnosis, human epidemidin protein 4: A preliminary study. Mol and Clin Oncol. 2016 May; 5: 355 – 360. DOI: 10.3892/mco.2016.919.

27. AL-Bedairy IH, AL-Faisal AHM, AL-Gazali HR, AL-Mudhafar H. Molecular Subtypes by Immunohistochemical for Iraqi Women with Breast Cancer. Iraqi J of Biotechnol. 2020 Apr [2020 Apr 30]; 19 (1): 19-28.

28. Chasib ThJ, Al-Hawaz M, Jasim NH. Evaluation of The Estrogen and Progestrone Receptors in Female Breast cancer in Respect to Age, Grade and Stage. Bas J Surg. 2013 Sep; 9 – 14.

29. Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal transduct. target. ther. 2019 Sep [2019 Aug 22] ; 4 (34): 1 – 22. Available from http://doi. Org DOI: 10.1038/s41392-019-0069-2.

30. Sareyeldin RM, Gupta I, Al-Hashimi I, Al-Thawadi HA, Al Farsi HF, Vranic S, et al. Gene Expression and miRNAs profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. Cancers. 2019 May; 11 (646): 1 – 20. DOI: 10.3390/cancers11050546.

31. Furrer D, Paquet C, Jacob S, Diorio C. The Human Epidermal Growth Factor Receptor 2 (HER2) as a prognostic and predictive biomarker: molecular insights into HER2 activation and diagnostic implications. IntechOpen. 2018: 11 – 3. Available from http://dx.doi.org DOI: 10.5772/intechopen.78271.

32. Chappuis PO, Donato E, Goffin JR, Wong N, Be'gin LR, Kapusta LR, et al. Cyclin E expression in breast cancer: predicting germine BRCA1 mutations, prognosis and response to treatment. Ann Oncol. 2004 Dec [2005 Mar 31]; 16: 735 – 742. DOI: 10.1093/annonc/mdi149.

33. Hwang HC, Clurman IS. Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005; 24: 2776 – 2786. DOI: 10.1038/sj.onc.1208613.

34. Ryu M, Sung CH, Im YJ, Chun CH. Activation of JNK and p38 in MCF-7 cells and the In Vitro Anticancer Activity of Alnus hirsute Extract. Molecules. 2020 Feb [2020 Feb 27]; 25(1073): 1-23. Available from www.mdpi.com/journal/molecules DOI: 10.3390/molecules2501073.

35. Kabiraj A, Gupta J, Khaitan T, Bhattacharya PT. Principle And Techniques of Immunohistochemistry-A Review. Int J Biol Med Res. 2015; 6(3): 5204-5210. Available from www.biomedsci.com.

36. Iqbal BM, Buch A. Hormone receptor (ER, PR, and HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. Medical J of Dr. D.Y. Patil Univ. 2016 [2016]: 9 (6): 674 – 679. DOI: 10.4103/0975-2870.194180.

37. Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, et al. Cytoplasmic Cyclin E and Phospho-Cyclin - Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer: The Am J of Pathol. 2016 Feb; 186 (7): 1900 – 1912. Available from http://dx.doi.org DOI: 10.1016/j.ajpath.2016.02.024.

38. Zhuangwei LV, Liu M, Shen J, Xiang D, Yunfeng MA, Yanhong J. Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases. Exper and Ther Med. 2018 Jan; 15: 5475 – 5480. DOI: 10.3892/etm.2018.6109.

39. Bhattacharjee HK, Bansal VK, Nepal B, Srivastava S, Dinda AK, Misra MC. Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis? Indian J Surg Oncol. 2016 Feb [2016 Feb 20]; 7 (3): 320 – 325. DOI: 10.1007/s13193-016-0512-6.

40. Qiao Y, He H, Jonsson P, Sinha I, Zhao Ch, Dahlman-Wright K. AP-1 Is a Key Regulator of Proinflammatory Cytokine TNF-α mediated Triplet-negative Breast Cancer Progression . The J of Biol chem. 2016 Jan; 291 (10): 5068 – 5079. DOI: 10.1074/jbc.M115.702571.

41. Carruba G, D’Agostino P, Miele M, Calabro M, Barbera C, Di Bella G, et al. Estrogen Regulates Cytokine Production and Apoptosis in PMA-Differentiated, Macrophage-Like U937 Cells. J of Cell Biochem. 2003 May; 90: 187 – 196. DOI: 10.1002/jcb.10607.

42. Yerushalmiv R, Tyldeles S, Kennecke H, Speers C, Woods R, Knight B, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann of Oncol. 2011 May; 23 (2): 338 – 345. DOI: 10.1093/annonc/mdr154.

43. Klee GG, Schreiber WE. MUC1 Gene-Derived Glycoprotein Assays for Monitoring Breast Cancer (CA 15-3, CA 27.29, and BR) Are They Measuring the Same Antigen? Arch Pathol Lab Med. 2004 Jun; 128: 1131 – 1135.

44. Conley SJ, Bosco EE, Tice DA, Hollingsworth RE, Herbst R, Xiao Z. HER2 drives Mucin-like 1 to control proliferation in breast cancer cells. Oncogene. 2015 Nov [2016 Jan 4]; 35: 4225 – 4234. DOI: 10.1038/onc.2015.487.

45. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, et al. Targeting the MUC1-C oncprotein downregulates Her-2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2014 Jun [2014 Dec 26]; 33 (26): 3422 – 3431. DOI: 10.1038/onc.2013.308.

46. Akoz G, Diniz G, Ekmecki S, Ekin ZY, Uncel M. Evaluation of human epidymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of
47. Zhu L, Zhuang H, Wang H, Tan M, Schwab CL, Deng L, et al. Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget. 2015 Oct; 1–16.

48. Hsu JL, Hung M-Ch. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016 Dec [2017 Dec 1]; 35 (4): 575 – 588. DOI: 10.1007/s10555-016-9649-6.

49. Wei L-H, Baumann H, Tracy E, Wang Y, Hutson A, Rose-John S, et al. Interleukin-6 Trans signalling enhances photodynamic therapy by modulating cell cycling. Brit J of Cancer. 2007 Oct [2007 Nov 6]; 97 : 1513 – 1522. DOI: 10.1038/sj.bjc.6604073.

50. Pan Y, Claret FX. Jab1/Csn5 Signaling in Breast Cancer. Intech. 2017; 199 – 211. Available from http://dx.doi.org DOI: 10.5772/66174.

51. Shackleford TJ, Claret FX. JAB1/CSN5: a new player in cell cycle control and cancer. Cell Division. 2010 [2010 ]; 5 ( 26 ): 1 – 14 . DOI: 10.1186/1747-1028-5-26.

52. Dhillon NK, Mudryj M. Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells. Genes Immun. 2002 Dec; 4: 336 – 342. DOI: 10.1038/sj.gene.6363973.

53. Lee AV, Oesterreich S, Davidson NE. MCF-7 Cells—Changing the Course of Breast Cancer Research and Care for 45 Years. JNCI J Natl Cancer Inst. 2015 Feb; 107 (7): 1 – 4. DOI: 10.1093/jncci/djv073.

54. Wang J, Deng L, Zhuang H, Liu J, Liu D, Li X, et al. Interaction of HE4 and ANXA2 exists in various malignant cells—HE4–ANXA2–MMP2 protein complex promotes cell migration. Cancer Cell Int. 2019 May [2019 Jun 13]; 19 (161): 1-12. Available from http://doi.org DOI: 10.1186/s12935-019-0864-4.

55. Gibbs LD, Chaudhary P, Mansheim K, Hare RJ, Mantsch RA, Vishwanatha JK. ANXA2 Expression in African American triple-negative breast cancer patients. Breast Cancer Res and Treat. 2018 Oct [2018 Nov 26]; 1 – 8. Available from http://doi.org DOI: 10.1007/s10549-018-5030-5.

56. Wu M, Sun Y, Xu F, Liang Y, Liu H, Yi Y. Annexin A2 Silencing Inhibits Proliferation and Epithelial-to mesenchymal Transition through p53-Dependent Pathway in NSCLCs. J of Cancer. 2019 Jan; 10 (5): 1077 – 1085. DOI: 10.7150/jca.29440.

57. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, et al. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J of Cancer. 2017 Jul; 8 (1): 2004 – 2009. DOI: 10.7150/jca.18196.

58. Alawadi AF, Al-Nuaimi DS, Al-Naqash MA, Alshewered AS. Time to Progression of Early Versus Advanced Breast Cancer in Iraq. La Prensa Medica Argentina. 2019 Dec [2020 Jan 2]; 106 (1): 1 – 5.

59. Al Zobair AA, Jasim BI, Al Obeidy BF, Jawher NMT. Prognostic impact of hormone and HER2 status on the prognosis of breast cancer in Mosul. Ann. Trop. Med. Public Health. 2020 Apr; 23(7): 844 – 854. Available from http://doi.org DOI: 10.36295/ASRO.2020.2375.

60. Goldvaser H, Kozrets Y, Shepshtelovich D, Yerushalmi R, Sarfati M, Ribnikar D, et al. Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectrum. 2019 Mar[2019 Apr 26]; 3(2): 1 – 8. Available from http://creativecommons.org/licenses/by-nc/4.0/ DOI: 10.1093/jncics/pkz033.

61. Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, et al. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2016 Nov[2017 Jun 15]; 23(12): 2991 – 3002. Available from www.aacrjournals.org DOI: 10.1158/1078-0432.CCR-16-2217.

62. Delk NA, Hunt KK, Keyomarsi K. Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation. Cancer Res. 2009 Apr; 69(7): 2817 – 2825. Available from PMC DOI: 10.1158/0008-5472.CAN-08-4182.
العلاقة بين معلمات المصل و النسيج في المصابات العراقيات بسرطان الثدي

عبير محمد حسين علي1، حيدر لطيف محمد2

1قسم طوم الطبيه، كلية العلوم للبنات، جامعة بغداد، بغداد، العراق
2استشاري علم الأمراض (بورد في طب المجتمع - بكلايروسي طب وجراحة عامة ) وزارة الصحة/مستشفى التعليمي والذي

الخلاصة:

يعتبر سرطان الثدي من أكثر الأورام الخبيثة انتشارًا بين النساء في جميع أنحاء العالم، وفي العراق يحتل المرتبة الأولى والسبب الرئيسي لوفيات الإناث المرتبطة بالسرطان. تم تصميم هذه الدراسة لبحث العلاقات بين معلمات المصل والনسيج من أجل توضيح دورها في تطور أو تراجع سرطان الثدي. معلمات الورم هي مجموعة من المواد، تكون بشكل رئيسي ذات طبيعة بروتينية، تنتج من الخلايا السرطانية أو من خلايا أخرى في الجسم استجابة للورم. أجريت الدراسة في الفترة من أبريل 2018 إلى أبريل 2019 بإجمالي عدد 60 آمال مصابة بسرطان الثدي. تم جمع عينات الدم من النساء المصابات بسرطان الثدي في فترة ما بعد الجراحة وما قبل العلاج اللاثي حضرن إلى مستشفى الأورام التعليمي في مدينة الطيب في بغداد. تم تقييم معلمات المصل بتقنية ELISA وهي Carbohydrate Antigen 15-3 (CA 15-3) و Carbohydrate Antigen 29 (CA 29). تم جمع عينات الأنسجة لنفس النساء المصابات بسرطان الثدي اللى حضرن إلى مدينة الطيب، بغداد بإجمالي عدد 30. تم تقييم معلمات الأنسجة باستخدام تقنية الكيمياء المناعية وهي مستقبلات هرمون الاستروجين (ER) ، مستقبل هرمون الاستروجين (PR) ، مستقبلات البروجسترون (E2) ، مستقبل الاستروجين (ER) هرمون مضاد مولر (AMH) ، عامل نخر الورم ألفا (TNF-α) ، بروتين البربخ البشري 4 (HE4) ، عامل نخر الورم ألفا (AMH) ، عامل نخر الورم ألفا (TNF-α) ، بروتين البربخ البشري 4 (HE4) ، عامل نخر الورم ألفا (AMH) ، عامل نخر الورم ألفا (TNF-α) ، بروتين البربخ البشري 4 (HE4) ، عامل نخر الورم ألفا (AMH) ، عامل نخر الورم ألفا (TNF-α) ، بروتين البربخ البشري 4 (HE4) ، عامل نخر الورم ألفا (AMH) ، عامل نخر الورم ألفا (TNF-α) ، بروتين البربخ البشري 4 (HE4) ، عامل نخر الورم ألفا (AMH) ، عامل نخر الورم ألفا (TNF-α) ، بروتين البربخ البشري 4 (HE4) ، عامل نخر الورم ألفا (AMH) ، عامل نخر الورم ألفا (TNF-α) ، بروتين البربخ البشري 4 (HE4).

الكلمات المفتاحية: هرمون مضاد مولر (AMH) ، سرطان الثدي (Ca 15-3) ، مستقبل هرمون الاستروجين (ER) ، بروتين البربخ البشري 4 (HE4)